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Abstract
Many cell lines derived from tumors as well as transformed cell lines are far more sensitive to V-ATPase inhibitors than
normal counterparts. The molecular mechanisms underlying these differences in sensitivity are not known. Using global
gene expression data, we show that the most sensitive responses to HeLa cells to low doses of V-ATPase inhibitors involve
genes responsive to decreasing intracellular iron or decreasing cholesterol and that sensitivity to iron uptake is an important
determinant of V-ATPase sensitivity in several cancer cell lines. One of the most sensitive cell lines, melanoma derived SK-
Mel-5, over-expresses the iron efflux transporter ferroportin and has decreased expression of proteins involved in iron
uptake, suggesting that it actively suppresses cytoplasmic iron. SK-Mel-5 cells have increased production of reactive oxygen
species and may be seeking to limit additional production of ROS by iron.
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Introduction
Inhibitors of the vacuolar-type (H+)-ATPase (V-ATPase) have
been investigated as potential therapeutics for cancer [1,2] as they
show impressive differential cytotoxicity for the 60 cell lines of the
NCI COMPARE panel. Additionally, cell lines transformed with
oncogenes are more sensitive to V-ATPase inhibitors than are the
parental, untransformed cell lines [3,4]. Many cancer cell lines
upregulate expression of V-ATPase subunits compared to normal
tissues [1] and V-ATPases are thought to play a role in metastasis
[5,6] and chemoresistance [2,7]. However, the fundamental
mechanisms that determine which cancer cells are most sensitive
to V-ATPase inhibitors are currently unknown. This is important
knowledge, as inhibiting the V-ATPase itself can inhibit synaptic
transmission [8]. Thus proteins involved in cellular processes that
are most differentially sensitive to inhibition of the V-ATPase
might be better therapeutic targets than the V-ATPase itself.
The V-ATPase is a large, protein complex that can transport
protons across membranes against a pH gradient and thus
generate the acidic environment found in endocytic organelles,
the Golgi apparatus and the Trans-Golgi Network [9]. It is
composed of a large, cytosolic hexameric ATPase, V1, that is
joined by several linkages to an integral membrane complex, V0.
Hydrolysis of ATP by subunits of V1 is converted into mechanical
rotation in V0 that moves protons from the cytosolic to the
lumenal side of the membrane in which V0 resides. The activity of
the V-ATPase is controlled by multiple mechanisms so that when
disassembled, V1 does not hydrolyze ATP and V0 does not rotate
and transport protons [9]. A number of inhibitors of the V-
ATPase are known that have distinct binding sites [10].
In both the secretory and the endocytic pathways pH gradients
are critical for many functions. The lumen of the endoplasmic
reticulum is neutral and that of the Golgi complex is acidic and
this difference is used to regulate the binding of escaped ER
chaperones in the acidic Golgi by the KDEL receptor, which
recycles to release them at the neutral ER [11]. pH decreases
across the Golgi complex, so that prohormone convertases are
activated at the acidic exit face of the trans-Golgi network and in
secretory vesicles, but not earlier in the pathway [12]. In a similar
fashion, many lysosomal proenzymes are inactive at the pH of the
secretory pathway and are activated after reaching the lysosome,
where the pH is usually below 5.0 [13]. In the endocytic pathway,
certain ligands, such as low density lipoproteins (LDL), bind
receptors at neutral pH at the cell surface and are released when
the receptors reach acidic endosomes [14]. In this way LDL is
efficiently taken up by the cell and delivers its cargo of cholesterol
to lysosomes while the receptor recycles to the cell surface to bind
more ligand. Efficient uptake of iron into cells also requires low pH
in endosomes. Transferrin, the carrier for extracellular iron, has
high affinity for iron and for its cell surface receptor at typical
extracellular pH above 7.0. The transferrin receptor is continually
internalized and recycles to the plasma membrane, carrying
transferrin to acidic endosomes where it releases iron. Iron-free
apotransferrin has high affinity for the receptor at low pH and low
affinity at neutral pH. Thus, apotransferrin recycles with its
receptor back to the plasma membrane where it is released and
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used to establish the identity of endocytic organelles. Certain
cytosolic proteins required for regulating membrane traffic bind to
the cytoplasmic face of endosome membranes only when the
internal pH of the organelle is acidic [16]. Acidification of
lysosomes is also required for the process of autophagy [17].
Although normally expressed at low levels at the plasma
membrane except in certain acid secreting cells, V-ATPase is
over-expressed at the plasma membrane of some cancer cells and
may play a role regulating cytosolic pH [5,6,18]. Any or all of
these essential functions might be more vulnerable to inhibition of
the V-ATPase in particular cancer cell backgrounds.
Toinvestigate the basis forthe differential sensitivityofcancercells
to inhibitors of the V-ATPase, we have made use of the observation
that cells often respond to stress by up-regulating critical components
of pathways that are sensed to be failing, as for example the response
to the failure of protein folding in the endoplasmic reticulum [19].
Our hypothesis is that a mild inhibition of the V-ATPase will reveal
the most sensitive biological functions for that enzyme, which will be
indicated by genes that first increase transcription in response to the
inhibition. Testing this hypothesis, we have observed that pathways
of iron regulation are most sensitive to partial inhibition of the V-
ATPase in HeLa cells and that some cancer cell lines most sensitive
to V-ATPase inhibitors can be made much more resistant by adding
exogenous iron to the culture medium. This suggests that
components of iron metabolism or transport may be candidates as
therapeutic targets in certain cancers, and these cancers may be
identified through their sensitivity to V-ATPase inhibitors or by
changed expression of iron transport proteins.
Results
To determine which metabolic pathways were stressed by low
doses of V-ATPase inhibitors, we first determined the dose
response to two different inhibitors of the V-ATPase on several cell
lines. We wished to find a concentration of each inhibitor that
would show an effect on growth, indicating that cells were
responding to the stimulus, but which was not so toxic that the
response would be prevented or complicated by cells dying during
the experiment. The cell lines we tested had IC50s to bafilomycin
A that ranged from 10 nM to greater than 10 mM and we chose
the moderately sensitive cell line HeLa (IC50=150 nM) for our
experiments because its relatively shallow dose response made for
more uniform growth inhibition experiments, suggesting that the
gene expression experiments would also be more reproducible. We
also chose to compare two inhibitors of the V-ATPase that act
through distinct mechanisms [20], bafilomycin A (Baf) and
phenylsalicylihalamide (LX1077), to control for possible off-target
effects of each compound. Concentrations of each compound that
inhibited cell growth approximately 25% after 48 hours (Figure 1)
were chosen for the gene expression experiments. HeLa cells were
cultured overnight and then samples were treated with 15 nM Baf
for 6, 12, or 24 hours, or 200 nM LX1077 for 12 and 24 hours,
and RNA was harvested and processed for analysis by microarray.
As controls, samples of HeLa cells treated for the same interval
with 0.1% DMSO (the final concentration of the diluent for Baf or
LX1077 in experimental samples), were run in parallel with each
experimental condition. Each experimental condition was repeat-
ed in an independent experiment conducted on a different day.
Two major pathwaysfor uptake ofnutrientsinto cellsdepend upon
the acidity in endosomes supplied by the V-ATPase. Inhibiting the V-
ATPase will interfere with the delivery of iron into the cell by
preventing the release of iron from transferrin and also prevents
uptake of cholesterol by inhibiting the release of LDL from its
receptor. Therefore we treated HeLa cells for 6 or 12 hours with
deferoxamine (DFO) to chelate iron and separately with medium
lacking LDL to mimic inhibiting uptake of exogenous cholesterol
through the LDL receptor. Controls were matched samples cultured
in normal culture medium. These samples were processed for
microarrays exactly as samples treated with V-ATPase inhibitors. In
this way we could identify all genes responding by increased
transcription when iron was deficient or LDL uptake was blocked.
Data was processed by the UT Southwestern DNA Micro Array
Core Facility using GCOS software with MAS5 normalization and
experimental samples were compared to the DMSO treated samples,
or, for DFO or low LDL conditions, samples cultured in normal
medium run at the same time to calculate the magnitude of change.
Genes were considered to show significantly increased expres-
sion if both samples at one time point with either Baf or LX1077
had a change P value of less than 0.002 and the average of the two
samples increased more than 2-fold. In most cases, Baf induced
transcription more than LX1077, although the genes responding
to Baf also responded to LX1077. The genes that increased
transcription earliest are shown in Tables S1, S2 and Table 1.
Table S1 presents 47 genes that increased expression when HeLa
cells were treated with V-ATPase inhibitors or with low cholesterol
medium and represent the response to inhibiting the V-ATPase
that is due to blocking delivery of exogenous cholesterol. The
response of most of these genes is faster in the presence of the V-
ATPase inhibitors than it is to medium lacking LDL, perhaps
because medium lacking LDL does not block the delivery of
cholesterol from LDL particles that are either bound to their
receptor at the cell surface or already released into the endocytic
pathway at time the medium deficient in LDL was added. The
majority of the genes shown in Table S1 function in lipid
biosynthetic pathways and 23 are known targets of SREBP1 or 2
[21]. With the exception of EGLN1 and STARD4, none of the
genes that increase transcription early in response to low LDL
respond to the iron chelator DFO. EGLN1 encodes an iron-
dependent prolylhydroxylase that represses Hif-1a activity under
normoxic conditions [22] and is not known to be sensitive to the
activity of the cholesterol biosynthetic pathway. However, in yeast
and mammals there is cross-talk between cholesterol biosynthesis
and pathways of adaptation to hypoxia [23,24]. STARD4 encodes
a cytosolic cholesterol transfer protein that is an SREBP target
Figure 1. Dose-response of HeLa cells to BafA or LX1077. HeLa
cells were cultured in medium containing BafA or LX1077 at the
concentrations shown for 48 hours and cell numbers were calculated.
Data is normalized to controls treated with 0.1% DMSO. Data are
averages of triplicate samples and error bars are SEM.
doi:10.1371/journal.pone.0011629.g001
Response to V-ATPase Inhibitor
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indirectly upregulated by the iron chelator. Interestingly, increased
transcription of INSIG1, encoding a negative regulator of the
SREBP transcription factors that control cholesterol biosynthesis,
is one of the faster responses to V-ATPase inhibitors. This is
possibly a negative feedback mechanism to limit the transcrip-
tional response once lipid metabolic pathways have increased
production of endogenous cholesterol [26].
Table S2 lists 64 genes that increased transcription fastest when
iron was chelated and also respond to inhibition of the V-ATPase.
These are genes in pathways that presumably respond to the
inhibition of iron release by transferrin in endosomes when the V-
ATPase is inhibited. At least 29 of these genes are known targets of
Hif-1a and respond to hypoxia. As one would expect, these genes
function in many pathways. Aldolase C is a Hif-1a target[27] and is
strongly upregulated by V-ATPase inhibitors. Although we did not
detect an early increase in aldolase C in cells treated with low LDL
medium,aldolaseC isalsoa known targetofSREBPs[21].Aldolase
C binds to the V-ATPase [28] and in yeast is responsible for glucose
regulation of V-ATPase activity [29,30]. Since aldolase C responds
to hypoxia in lung epithelial cells and to V-ATPase inhibitors in
HeLa cells, whereas the more abundant glycolytic enzyme aldolase
A does not, it is possible that a major function of aldolase C in
response to lack of iron or hypoxia is to regulate the V-ATPase as
part of the mechanism to ensure iron homeostasis. Hif-1a is
repressed primarily by being hydroxylated on proline by iron-
dependent prolyhydroxylases, which targets it for degradation [31].
By immunoblot we found that incubating HeLa cells in 15 nM Baf
for1 hrstabilizedHif-1a (datanot shown),suggestingthat pathways
regulatedbyHif-1a areamongthe most sensitivetoinhibition ofthe
V-ATPase. Thus, V-ATPase inhibitors provide a most effective
means for engaging Hif-1a pathways experimentally.
Table 1 presents 7 genes that increased transcription in response
to V-ATPase inhibitors, but not in HeLa cells treated with low
LDL medium or with the iron chelator. These are candidates for
pathways that sense the lack of V-ATPase activity independently
of the effect on transferrin or LDL. Other than CLCN6, these
genes are not strongly upregulated and several of them are
involved in the cell cycle and growth control and may be an early
part of the growth inhibition that will occur after longer incubation
in the inhibitors. CLCN6 is a chloride channel found in neurons
and epithelial cells [32,33], and localizes to late endosomes [33].
Table 1. Genes Increasing Expression Early with V-ATPase Inhibitors and not with DFO or Low LDL.
Fold Increase Relative to Control
Gene Name Function or Pathway
Baf 6
hr
Baf 12
hr
LX 12
hr
DFO
6h r
DFO
12 h
low LDL
6h r
low LDL
12 hr
CCNG2 cyclin G2 cell cycle control 1.5 2.0 2.0 NC NC NC NC
CLCN6 chloride channel 6, isoform ClC-6a chloride transport 8.0 2.1 NC NC NC NC NC
DUSP6 dual specificity phosphatase 6 inactivates ERK2 2.3 2.6 NC NC NC NC NC
FADSD6 delta-6 fatty acid desaturase lipid biosynthersis 1.7 3.4 2.4 NC NC NC NC
SREBF2 sterol regulatory element binding
transcription factor 2
cholesterol biosynthesis 1.5 2.0 NC NC NC NC NC
TUBA1A tubulin, alpha 1a microtubule protein 1.3 2.1 1.4 NC NC NC NC
WDR37 WD repeat domain 37 unknown 1.9 1.9 NC NC NC NC NC
Genes upregulated 2-fold or more after 12 hours in cells treated with V-ATPase inhibitors and in cells treated with 100 mM deferoxamine are listed. Baf, 15 nM
bafilomycin A; LX, 200 nM LX1077; DFO, 100 mM deferoxamine; low LDL, cells incubated in medium containing LDL depleted serum.
doi:10.1371/journal.pone.0011629.t001
Table 2. Pathways significantly enriched in genes changing expression after 6 h treatment with 15 nM bafilomycin.
Ingenuity Canonical
Pathways
-log
p value Ratio Down
No change or
Not present Up Molecules
Biosynthesis of Steroids 12.40 0.09 0/128 117/128 11/128 FDPS, MVK, SC5DL, FDFT1, SQLE, EBP, IDI1, DHCR7, HMGCR,
LSS, MVD
Glycolysis & Gluconeogenesis 4.10 0.06 0/142 134/142 8/142 GNE, PGM1, ALDOA, ALDOC, PGK1, ENO2, ACSS2, HK2
Fructose & Mannose Metabolism 3.72 0.04 0/145 139/145 6/145 GNE, PFKFB3, ALDOA, ALDOC, PFKFB4, HK2
TR/RXR Activation 3.64 0.07 1/97 90/97 6/97 SLC2A1, SLC16A3, PIK3C2A, LDLR, DIO2, SREBF2, FASN
Inositol Metabolism 3.61 0.07 0/98 91/98 7/98 FADS1, ALDOA, DHCR24, ALDOC, RDH11, SC4MOL, ERO1L
HIF1a Signaling 3.19 0.06 1/108 101/108 6/108 EGLN1, SLC2A1, VEGFA, EGLN3, SLC2A3, PIK3C2A, EDN1
AMPK Signaling 2.56 0.04 0/165 158/165 7/165 PFKFB3, IRS2, PIK3C2A, HMGCR, PFKFB4, AK3L1, FASN
RCC Signaling 2.54 0.07 0/72 67/72 5/72 SLC2A1, VEGFA, EGLN3, MAP2K1, PIK3C2A
Ovarian Cancer Signaling 2.04 0.04 1/135 129/135 5/135 PTGS2, VEGFA, FZD8, MAP2K1, PIK3C2A, EDN1
IGF-1 Signaling 1.99 0.05 1/100 95/100 4/100 GRB10, IRS2, MAP2K1, PIK3C2A, CYR61
Genes changing significantly in duplicate experiments were analyzed with Ingenuity Pathways Analysis software to identify pathways in which a statistically significant
number of genes were changed. Only pathways with a –log p value greater than 2 by Fisher’s exact T-test are shown. The ‘‘ratio’’ is the fraction of total genes assigned
to the pathway that changed expression.
doi:10.1371/journal.pone.0011629.t002
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and thus CLCN6 upregulation may be a response to loss of late
endosome function. SREBF2 (SREBP2) is a major regulator of
cholesterol biosynthesis and it is primarily regulated post-
transcription by membrane traffic and proteolysis [34]. The
modest transcriptional increase is likely balanced by the increase in
expression of the inhibitor of SREBP activation, INSIG1.
Table 2 presents the results of taking a less restrictive analysis of
the genes that change in HeLa cells treated with 15 nM Baf for
6 hr. All genes that showed a statistically significant change
(change P value .0.00025) regardless of the direction of change
were analyzed with Ingenuity Pathways to determine which
canonical pathways in the Ingenuity Database were enriched in
genes that were changed in response to Baf. Pathways that
responded significantly to Baf contained very few genes that
decreased expression, confirming our assumption that the early
response would be increased gene expression. By far the most
significantly affected pathways were steroid biosynthesis, followed
by glycolysis, and involved genes for the most part also identified
by our more restrictive analysis.
After longer intervals of treatment with V-ATPase inhibitors, 52
genesthat hadincreasedinresponseto12 hours culture inlowLDL
medium also showed increased expression in cells treated for
24 hours with V-ATPase inhibitors (Table S3). Eight of the
cholesterol responsive genes that were upregulated earlier no longer
showedanincrease and 15newcholesterol responsivegenesshowed
increased transcription, with 6 of these encoding proteins involved
in lipid biosynthetic pathways. 104 ‘‘iron responsive’’ genes (Table
S4) were increased in cells treated with V-ATPase inhibitors for
24 hours, including a number of genes encoding glycolytic enzymes
or repressors of mitochondrial function, transcription factors and
proteins regulating cell growth. STXBP1, which encodes the
MUNC-18 regulator of membrane fusion, showed modest increase
in response to either depleting cholesterol or iron and a stronger
increase in cells treated with V-ATPase inhibitors. This is one of the
very few genes encoding proteins that regulate membrane traffic
that increased in response to inhibiting the V-ATPase (HIP1R,
SV2A and OPTN were the others). Sixty two genes increased
expression at least two-fold in response to inhibiting the V-ATPase
for 24 hours,butdidnot respond to cholesteroldeficient medium or
DFO (Table S5). This set of genes was analyzed using Ingenuity
Pathways software to identify metabolic pathways in which genes
were significantly upregulated (Figure 2). By far the most significant
response was in genes involved in lipid and steroid biosynthesis.
As one would expect, if both increases and decreases in gene
expression are considered, after 24 hours in Baf there is a
complicated response involving a number of pathways that control
growth and response to stress (Table S6). The most significant of
these is the NRF2-mediated oxidative stress response, suggesting
that inhibiting the V-ATPase increases reactive oxygen species. As
Figure 2. Metabolic functions of genes increasing expression after 24 hours in response to inhibitors of V-ATPase, but not
responding to low cholesterol or iron chelation. The genes in Table S4 were analyzed with Ingenuity Pathways to assign them to canonical
pathways. The percent of genes in the pathway represented in this data set, and the significance of the change are shown.
doi:10.1371/journal.pone.0011629.g002
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require iron, and inhibition of oxidative phosphorylation can
produce ROS, changes in NRF2 mediated pathways could be a
secondary consequence of inhibiting iron import from transferrin.
Our original intent in pursuing these studies was to investigate
the causes of differential response to V-ATPase inhibitors seen in
cancer cells. Because the major immediate responses to inhibition
of the V-ATPase were to the lack of iron or cholesterol, we
investigated if these were responsible for the hypersensitivity of
some cancer cells to V-ATPase inhibitors (Figure 3). We measured
the dose-response of cervical cancer derived HeLa, melanoma
derived cell lines SK-Mel-5 and SK-Mel-28, non-small cell lung
cancer line H1299, breast cancer MCF-7 and Morris Hepatoma
(MH) cells to Baf in the presence or absence of 150 mM iron
citrate. Baf had very similar IC50 concentrations for HeLa, MCF7
and H1299. Both MH and SK-Mel-5 cells were 10-fold more
Figure 3. Iron supplement desensitizes cancer cell lines to bafilomycin. The dose-response of six cancer cell lines to Baf in the presence or
absence of 150 mM iron citrate was determined as described in the legend to figure 1.
doi:10.1371/journal.pone.0011629.g003
Response to V-ATPase Inhibitor
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(Figure 3). For Hela, SK-Mel-5 and SK-Mel-28 we also tested the
effect of adding cholesterol delivered into cells with methy-b-
cyclodextrin, which adds cholesterol directly to the plasma
membrane [26]. Adding iron to the medium made HeLa cells
20-fold more resistant to growth inhibition caused by 20 to
200 nM bafilomycin, but provided little protection to the cytotoxic
effects observed at higher concentrations (Figure 3). Cholesterol
was protective for HeLa cells, but not for the Baf-sensitive SK-
Mel-5 cells or Baf resistant SK-Mel-28 (Figure 4). This indicates
that the cytostatic effects of V-ATPase inhibitors in HeLa cells are
largely due to the inhibition of iron and cholesterol uptake, but the
cytotoxic effects are due to an alternative, and as yet unknown,
function. Supplementing H1299, MCF7 or the more sensitive SK-
Mel-5 melanoma cell line with iron protected them at lower
concentrations of Baf similar to HeLa cells (Figure 3). In fact,
MCF7 or SK-Mel-5 cells treated with iron and bafilomycin had a
dose response remarkably similar to HeLa cells treated with
bafilomycin alone, suggesting that these cell lines were particularly
sensitive to inhibition of iron uptake. Neither iron nor cholesterol
had any protective effect on the highly resistant cell line SK-Mel-
28 or the quite sensitive MH cell line.
To investigate the mechanism of cytotoxicity induced by Baf in
SK-Mel-5 and HeLa cells, we treated cells of each line with 0 to
1000 nM Baf for 24 hours and then investigated the cleavage of
PARP or caspase 3 as signs for the induction of apoptosis
(Figure 5). In both cell lines Baf induced apoptosis after 24 hours;
however, the concentration required was over 20-fold lower for
SK-Mel-5 than HeLa cells, very similar to the differences in lethal
doses for the two cell lines. Thus, the cytotoxicity resulting from
inhibiting the V-ATPase in the hypersensitive cell line SK-Mel-5 is
through induction of apoptosis.
Both SK-Mel-5 cells and MCF7 cells were more sensitive to Baf
than HeLa cells and this difference in sensitivity was abolished by
supplementing the culture medium with iron (Figure 3). Thus we
investigated the expression of proteins involved in iron uptake,
storage or efflux in these cell lines and HeLa cells (Figure 6). SK-
Mel-5 cells expressed less transferrin receptor than either of the
other two cell lines and very low levels of DMT1, the transporter
responsible from moving iron across the endosome membrane to
the cytoplasm. Remarkably, SK-Mel-5 cells expressed high levels
of the iron efflux transporter, ferroportin, which transports iron
across the plasma membrane and out of the cell. Ferroportin was
not detected in either of the other two cell lines. SK-Mel-5 cells
expressed less ferritin than HeLa cells, consistent with having low
levels of cytoplasmic iron. Taken together, this pattern of
expression suggested that SK-Mel-5 cells were actively maintain-
ing relatively low cytoplasmic iron levels. In contrast, MCF7 cells
had levels of transferrin receptor similar to HeLa cells, increased
expression of DMT1 and very low levels of the iron storage
protein, ferritin. This is a pattern of expression consistent with a
cell that has low cytoplasmic iron levels and has upregulated iron
transport mechanisms in response. Thus, SK-Mel-5 cells and
MCF7 cells, although both hypersensitive to Baf due to inhibition
of iron uptake, differed in the molecular mechanisms underlying
this vulnerability.
The differences in expression of transferrin receptor and
ferroportin in SK-Mel-5 cells were not due to an inability to
regulate these proteins in response to iron. When SK-Mel-5 cells
or HeLa cells were treated with DFO to chelate iron, both
upregulated expression of transferrin receptor (Figure 7). In
response to DFO, transferrin receptor expression in SK-Mel-5
cells was very similar to that in HeLa, indicating that mechanisms
for expressing the receptor in response to iron were intact in SK-
Mel-5 cells. DFO treatment decreased the expression of
ferroportin and ferritin in SK-Mel-5 cells, as one would expect
for a cell striving to maintain cellular iron levels. Thus,
mechanisms for regulating these proteins by iron were also intact
in SK-Mel-5 cells. When SK-Mel-5 cells were treated with Baf,
they also increased expression of the transferrin receptor and
decreased ferritin. However, ferroportin expression was signifi-
cantly increased. Since chelating iron decreased ferroportin
expression in SK-Mel-5 cells, this response was due to some other
effect of inhibiting the V-ATPase.
Figure 4. Cholesterol supplement does not desensitize SK-Mel-
5 cells to bafilomycin. The dose response curves of HeLa, SK-MeL-5
and SK-Mel-28 cells to Baf in the presence or absence of exogenous
cholesterol delivered to cells by methyl-b-cyclodextrin was determined
as described in the legend to figure 1.
doi:10.1371/journal.pone.0011629.g004
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levels would be to protect against the generation of reactive oxygen
species (ROS) by iron. To investigate if SK-Mel-5 cells might be
producing more ROS, we labeled SK-Mel-5 and HeLa cells with
dyes that increase fluorescence in the presence of ROS. Cells were
photographed with identical camera settings and fluorescence
intensities of cells were measured using Image J software. SK-Mel-
5 cells produced significantly more ROS than HeLa cells,
measured with both dyes (Figure 8).
Since SK-Mel-5 cells appeared to have low levels of intracellular
iron and were hypersensitive to Baf, which would further decrease
iron uptake, we investigated the sensitivity of SK-Mel-5 cells to the
iron chelator DFO (Figure 9). As expected, SK-Mel-5 cells were
hypersensitive to DFO compared to HeLa cells. In fact, DFO was
only cytostatic for HeLa cells, whereas it was cytotoxic for SK-
Mel-5. Adding exogenous iron to the cell culture medium of SK-
Mel-5 or HeLa cells had no effect on cell growth (data not shown).
Three observations suggested that ferroportin expression might
be induced by ROS in SK-Mel-5 cells. SK-Mel-5 cells had both
increased ROS production and increased ferroportin expression.
One of the major pathways induced by Baf treatment of HeLa
cells for 24 hr was the antioxidant response mediated by NRF2,
suggesting that Baf treatment could increase ROS. Baf induced
rather than repressed ferroportin expression in SK-Mel-5 cells,
whereas lowering iron levels with DFO decreased ferroportin
expression. If ferroportin expression was induced by ROS, then
treating SK-Mel-5 cells with the anti-oxidant N-acetylcysteine
(NAC) would be expected to decrease ferroportin expression.
When SK-Mel-5 cells were treated for 48 hrs with increasing
concentrations of NAC, ferroportin expression was decreased
(Figure 10). Taken together, our data suggest that SK-Mel-5 cells
are vulnerable to inhibition of iron uptake because they maintain
low iron reserves, perhaps to protect themselves from generating
toxic levels of ROS.
Discussion
Although a number of cell lines derived from tumors or cell lines
transformed by oncogenes are highly sensitive to V-ATPase
inhibitors, problems of toxicity in animals, particularly neurotox-
icity, have prevented development of these inhibitors as anti-
cancer agents. The obvious problem is that the V-ATPase is an
important enzyme responsible for many fundamental cellular
processes and inhibiting it will have many effects in many cell
types. This in turn suggests that the hypersensitivity of cancer cells
to V-ATPase inhibitors should be due to a vulnerability in one or
more of the many processes requiring the V-ATPase and that
identifying these vulnerabilities might reveal therapeutic targets
that can be exploited with fewer toxic effects on normal tissues.
Our data show that inhibition of iron uptake by V-ATPase
inhibitors is an important determinant of differential sensitivity of
cancer cell lines to these inhibitors, suggesting that mechanisms
that control intracellular iron levels might be useful therapeutic
targets for certain tumors. Analysis of gene networks upregulated
in response to low doses of V-ATPase inhibitors revealed that
pathways responsive to decrease in intracellular iron and decrease
in exogenous cholesterol were by far the dominant responses, but
only iron was related to the hypersensitivity of several cancer cell
lines to V-ATPase inhibitors. Our results also indicate that there
are multiple mechanisms by which cancer cells are hypersensitive
to V-ATPase inhibitors and suggest that measuring the levels of
proteins involved in iron uptake, storage and efflux may be useful
for identifying tumors that might respond to therapeutics that
target iron. Although as rapidly growing cells, one might expect
that cancer cells in general might need more iron than normal
cells, SK-Mel-5 cells are an example of a cancer-derived cell that
appears to be actively limiting intracellular iron through the
expression of the efflux transporter, ferroportin. The vulnerability
of SK-Mel-5 cells to Baf and the iron chelator DFO is likely to be
due to higher than normal production of ROS. Future studies will
determine if this is the case and if these higher ROS levels can be
manipulated therapeutically. Ferroportin expression might be a
particularly good diagnostic for tumors that would be hypersen-
sitive to iron chelators, or to other means of therapeutically
increasing ROS.
Figure 5. Bafilomycin induces apoptosis. HeLa and SK-Mel-5 cells were treated with indicated concentrations of Baf for 24 hrs and then
prepared for immunoblotting with antibodies to cleaved PARP or cleaved caspase 3. The cleaved proteins appear at much lower concentrations of
Baf in SK-Mel-5 cells compared to HeLa, with the concentration difference between the appearance of cleaved protein similar to the differences in
lethal doses for the two cell lines. The immunoblots shown are representative of two independent experiments.
doi:10.1371/journal.pone.0011629.g005
Figure 6. The expression of proteins involved in iron transport
in SK-Mel-5 cells indicates a decrease in iron stores. The
expression of transferrin receptor 1, ferritin and ferroportin in HeLa and
SK-Mel-5 cells in the presence or absence of DFO was measured by
immunoblotting. Relative to HeLa cells, SK-Mel-5 have decreased
expression of transferrin receptor and ferritin and a large increase in
expression of the iron efflux protein ferroportin. TfR, transferrin
receptor. DMT1, divalent metal transporter 1. FPN1, ferroportin 1.
FTH, ferritin H heavy chain. The immunoblots shown are representative
of two independent experiments.
doi:10.1371/journal.pone.0011629.g006
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Antibodies
The following antibody were used in the study: mouse
monoclonal anti – transferrin receptor, cat. # 612124 from BD
Biosciences (San Jose, CA), rabbit polyclonal to metal transporter
protein (MTP1/IREG1/Ferroportin, cat. # MTP11-A from
Alpha Diagnostic International (San Antonio, TX), rabbit
polyclonal to divalent cation transporter 1/DMT1/NRAMP2/
Slc11a2, cat.# LS-C16687 from LifeSpan Biosciences (Seattle,
WA), rabbit polyclonal anti – ferritin FTH1, cat.# 3998, rabbit
polyclonal to cleaved PARP (Asp214) cat.# 9541, rabbit
polyclonal to cleaved caspase-3 (Asp175), cat.#9661 from Cell
Signaling Technology, Inc (Danvers, MA), mouse monoclonal
anti-actin, cat.# 69100 from MP Biomedicals (Aurora, Ohio).
Cell lines
HeLa, SK-MEL-5, SK-MEL-28, and MCF-7 cells were
obtained from the American Type Culture Collection. MH were
obtained from Ralph Mason (UT Southwestern) and H1993 from
John Minna (UT Southwestern). Cells were cultured in DMEM
with 10% fetal calf serum in 5% CO2 atmosphere at 37uC.
Dose-Response to Baf or LX1077 and iron rescue
1610
4 cells were added to wells in 96 well plates and the next
day a series of concentration of V-ATPase inhibitors or DMSO
was added to the wells. After 48 hours the ATP concentration in
the wells was measured with CelTiter Glo (Promega). For iron or
cholesterol rescue experiments either 150 mM iron citrate (Fe
3+)o r
30 mg/ml cholesterol with 2.5 mM methyl-b-cyclodextrin were
included in the medium with the V-ATPase inhibitors.
MicroArray Experiments
Actively growing HeLa cells were plated in 10 cm diameter
dishes in DMEM containing 10% fetal calf serum and grown
overnight to just reach confluency. Samples were treated with the
following conditions, 15 nM bafilomycin A (Sigma), 2001 nM
phenylsalicylihalamide (LX1077), 100 mM deferoxamine mesylate
(DFO, Sigma), or DME containing 10% LDL deficient serum
(provided by Joseph Goldstein and Michael Brown, UT
Southwestern). All samples except the low LDL and matched
controls received 0.1% DMSO. Cells were cultured in these
conditions for 6, 12, or 24 h and total RNA was isolated with
RNEasy Mini Kit (Invitrogen) and at least 2 mg RNA was
delivered to the UT Southwestern Microarray Core Facility.
Biotinylated cRNA were prepared according to the standard
Affymetrix protocol from 2 ug total RNA. Hybridizations to
Affymetriz Human Genome U133 Plus 2.0 Arrays and scanning of
the arrays with an Affy GeneChip 3000 7G, was conducted
according to the manufacturer’s instructions. Data was processed
with GCOS using MAS5.0 normalization to produce CHP files.
The microarray primary data, as CHP and CEL files, has been
uploaded to GEO under accession number GSE16870.
Ingenuity Canonical Pathways Analysis
The functional analysis of pathways enriched in genes which
changed expression after 6 or 24 hr treatment with Baf were
generated by Ingenuity Pathways Analysis (IngenuityH Systems,
www.ingenuity.com). The software calculates the significance of
the association between the data set, in this case all genes with a P
change value less than 0.00025, and genes assigned to canonical
pathways in the Ingenuity Knowledge Base. This significance is
based upon two factors, (1) the fraction of genes in the data set
assigned to a pathway compared to all genes assigned to that
pathway and (2) a p-value calculated by Fisher’s exact test that
determines the probability that this association arose by chance
alone.
Western blot analysis
To measure protein levels in response to DFO or Baf, cells were
treated with 100 mM DFO or 15 nM Baf for 24 hrs, or left
untreated, then washed with 1x PBS and lysed in 150 mM NaCl,
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 50 mM Tris,
pH 8 (RIPA buffer). Protein concentrations were determined using
DC Protein Assay (Bio-Rad, Hercules, CA) and 30 mg of total
protein for each sample was diluted with SDS sample buffer (EMD
Chemicals Inc., Gibbstown, NJ), boiled immediately for 15
minutes, and resolved by SDS/PAGE. Proteins were electro-
transferred to nitrocellulose membrane (Trans-Blot, Bio-Rad,
Hercules, CA) and probed with indicated primary antibody at
4uC, overnight. All antibodies were diluted with 5% Milk in 1x
PBS plus 0.5% TWEEN 20. All primary antibodies were used at a
dilution of 1:1,000, with the exception of actin, used at 1:10,000.
Secondary HRP-conjugated goat anti-rabbit and goat anti-mouse
antibody (Bio-Rad, Hercules, CA) were used at 1:3,000 dilution.
Protein bands were visualized using the ECL reagent (PerkinElmer
Figure 7. Iron regulation of transferrin receptor, ferroportin and ferritin is intact in SK-Mel-5 cells. Treatment of HeLa or SK-Mel-5 cells
with 100 mM DFO for 24 hrs resulted in increased expression of the transferrin receptor in both cell lines, and a decrease in ferroportin and ferritin in
SK-Mel-5 cells. Baf treatment had a similar effect, with the exception that ferroportin expression in SK-Mel-5 cells was increased by Baf. HeLa cells did
not express ferroportin and SK-Mel-5 cells had very low expression of DMT1. TfR, transferrin receptor. DMT1, divalent metal transporter 1. FPN1,
ferroportin 1. FTH, ferritin H heavy chain. The immunoblots shown are representative of two independent experiments.
doi:10.1371/journal.pone.0011629.g007
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PLoS ONE | www.plosone.org 8 July 2010 | Volume 5 | Issue 7 | e11629Figure 8. SK-MEL-5 have increased ROS. A. Cells were labeled with the H2O2 sensitive probe DCF, or the superoxide sensitive probe DHE, as
described in methods. Cells were photographed with identical camera settings. B. Fluorescent cells were outlined in Image J and the fluorescence
within individual cells was measured and graphed with GraphPad Prism.
doi:10.1371/journal.pone.0011629.g008
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growing HeLa, SKMEL5 and MCF7 cells were lysed in RIPA
buffer and 30 mg of protein was probed for the protein expression.
To measure apoptosis, HeLa and SK-Mel-5 cells were treated
with indicated concentrations of Baf for 24 hrs, then collected,
lysed in RIPA buffer and 30 mg of total protein was analyzed by
immunoblotting with antibodies to cleaved PARP or cleaved
caspase-3.
To measure the effect of N-acetyl-L-cysteine (NAC) on protein
expression, SKMEL5 cells were grown in the absence or presence
of 5 mM and 10 mM NAC, (Sigma, St. Louis, MO) for 48 hrs.
Medium containing NAC was changed every 8 hrs, with freshly
dissolved NAC. After 48 hrs treatment, cells were lysed in RIPA
buffer and 30 mg of total protein was analyzed by immunoblotting
with the antibodies shown. All Western blots shown are
representatives of two independent experiments performed on
different days with two independent sample sets.
Intracellular ROS measurements
5-(and-6)-chloromethyl-29,7 9-dichlorodihydrofluorescein diace-
tate, acetyl ester (CM-H2DCFDA), cat# C6827 (Invitrogen,
Carlsbad, CA) and dihydroethidium (DHE) cat# D23107
(Invitrogen, Carlsbad, CA) are cell permeable ROS-sensitive dyes,
that become fluorescent upon oxidation by ROS present in the
cytoplasm. The CM-H2DCFDA acts as an H2O2 –sensitive
probe, and DHE reacts mainly with superoxide anions [35]. The
amount of emitted fluorescence corresponds to the amount of
ROS present in the cell. For CM-H2DCFDA the excitation and
emission wavelengths were 488 nm and 530 nm, respectively, for
DHE the excitation and emission wavelengths were 518 nm and
605 nm, respectively. HeLa and SK-Mel-5 cells were grown on
glass coverslips in 12 well plates for 2 days prior the experiment,
then 25 mM of CM-H2DCFDA or 5 mM of DHA, freshly diluted
in the cell culture media, was added and plates returned back to
incubator for 2 hrs, for incubation at 37uC in the dark. After
incubation, cells were washed in PBS and fixed in 3.7% buffered
paraformaldehyde for 10 minutes, then washed with PBS and
mounted on glass slides with Prolong Gold mounting medium with
DAPI (Invitrogen, Carlsbad, CA). Cells were examined with a
DeltaVision deconvolution microscope and all images collected
with the same camera settings. Fluorescence intensity was measure
using Image J software and graphed with GraphPad Prism.
DFO sensitivity
To measure sensitivity to DFO, approximately 250,000 HeLa
or SK-Mel-5 cells were plated per well in 12-well tissue culture
plates. The next day, cells were treated with indicated dosages of
DFO, and 72 hrs later cell numbers were determined by using a
Beckman Cell Counter (Coulter, Miami, FL). Two wells for each
concentration were counted, and the average numbers of two
independent experiments were graphed +/2 SEM, n=2.
Supporting Information
Table S1 Genes Increasing Expression Early with V-ATPase
Inhibitors and with Low LDL. Genes upregulated 2-fold or more
after 12 hours in cells treated with V-ATPase inhibitors and in
cells incubated in medium lacking LDL are listed. Baf, 15 nM
bafilomycin A; LX, 200 nM LX1077; DFO, 100 mM deferox-
amine; low LDL, cells incubated in medium containing LDL
depleted serum.
Found at: doi:10.1371/journal.pone.0011629.s001 (0.12 MB
DOC)
Table S2 Genes Increasing Expression Early with V-ATPase
Inhibitors and with DFO. Genes upregulated 2-fold or more after
12 hours in cells treated with V-ATPase inhibitors and in cells
treated with 100 mM deferoxamine are listed. Baf, 15 nM
bafilomycin A; LX, 200 nM LX1077; DFO, 100 mM deferox-
amine; low LDL, cells incubated in medium containing LDL
depleted serum.
Found at: doi:10.1371/journal.pone.0011629.s002 (0.13 MB
DOC)
Table S3 Genes Increasing Expression Late with V-ATPase
Inhibitors and with Low LDL. Genes upregulated 2-fold or more
after 24 hours in cells treated with V-ATPase inhibitors and in
cells incubated in medium lacking LDL are listed. Baf, 15 nM
bafilomycin A; LX, 200 nM LX1077; DFO, 100 mM deferox-
amine; low LDL, cells incubated in medium containing LDL
depleted serum.
Found at: doi:10.1371/journal.pone.0011629.s003 (0.12 MB
DOC)
Figure 9. SK-Mel-5 cells are hypersensitive to DFO. Cells were
treated with the concentrations of DFO shown as described in Methods
and after 72 hours cells were counted. Two wells for each concentration
were counted, and the average numbers of two independent
experiments were graphed +/2 SEM, n=2.
doi:10.1371/journal.pone.0011629.g009
Figure 10. Ferroportin expression in SK-Mel-5 cells is decreased
by the antioxidant NAC. SK-Mel-5 cells were treated with NAC as
described in the Methods and then processed for immunoblotting with
antibodies against the proteins shown. TfR, transferrin receptor. FPN1,
ferroportin 1. FTH, ferritin H heavy chain. The immunoblots shown are
representative of two independent experiments.
doi:10.1371/journal.pone.0011629.g010
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PLoS ONE | www.plosone.org 10 July 2010 | Volume 5 | Issue 7 | e11629Table S4 Genes Increasing Expression Late with V-ATPase
Inhibitors and with DFO. Genes upregulated 2-fold or more after
24 hours in cells treated with V-ATPase inhibitors and in cells
treated with 100 mM deferoxamine are listed in order of increase
with Baf for 24 hours. Baf, 15 nM bafilomycin A; LX, 200 nM
LX1077; DFO, 100 mM deferoxamine; low LDL, cells incubated
in medium containing LDL depleted serum.
Found at: doi:10.1371/journal.pone.0011629.s004 (0.19 MB
DOC)
Table S5 Genes Increasing Expression Late with V-ATPase
Inhibitors and not with DFO or Low LDL. Genes upregulated 2-
fold or more after 24 hours in cells treated with V-ATPase
inhibitors and in cells treated with 100 mM deferoxamine are listed
in order of increase with Baf at 24 hours. Baf, 15 nM bafilomycin
A; LX, 200 nM LX1077; DFO, 100 mM deferoxamine; low LDL,
cells incubated in medium containing LDL depleted serum.
Found at: doi:10.1371/journal.pone.0011629.s005 (0.12 MB
DOC)
Table S6 Pathways significantly enriched in genes changing
expression after 24 h treatment with 15 nM bafilomycin. Genes
changing significantly in duplicate experiments were analyzed with
Ingenuity Pathways Analysis software to identify pathways in
which a statistically significant number of genes were changed.
Only pathways with a -log p value greater than 2 by Fisher’s exact
T-test are shown. The ‘‘ratio’’ is the fraction of total genes assigned
to the pathway that changed expression.
Found at: doi:10.1371/journal.pone.0011629.s006 (0.09 MB
DOC)
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